Skip to main content

Table 1 Demographic and baseline characteristics (safety analysis set)

From: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

  Treatment A Treatment B  
  PP 150 mg eq. PP 50-150 mg eq. Total
  (N = 186) (N = 26) (N = 212)
Age (years)
Mean (SD) 41.4 (10.24) 35.7 (8.17) 40.7 (10.17)
Sex, n (%)    
Men 138 (74) 16 (62) 154 (73)
Women 48 (26) 10 (38) 58 (27)
Race, n (%)
White 88 (47) 8 (31) 96 (45)
Black 36 (19) 6 (23) 42 (20)
Asian 60 (32) 12 (46) 72 (34)
Othera 2 (1) 0 2 (< 1)
Ethnicity, n (%)
Not Hispanic or Latino 184 (99) 24 (92) 208 (98)
Hispanic or Latino 2 (1) 2 (8) 4 (2)
Weight (kg)    
Mean (SD) 78.1 (18.55) 73.5 (16.45) 77.5 (18.33)
Height (cm)    
Mean (SD) 170.6 (10.24) 171.0 (9.97) 170.6 (10.18)
Baseline body mass index (kg/m 2)
Category, n (%)    
Normal < 25 70 (38) 14 (54) 84 (40)
Overweight 25- < 30 66 (35) 7 (27) 73 (34)
Obese ≥ 30 50 (27) 5 (19) 55 (26)
Mean (SD) 26.71 (5.55) 24.91 (4.16) 26.49 (5.42)
Psychiatric Evaluations b    
PANSS total scores, Mean (SD) 55.5 (8.87) 51.5 (9.86) 55.0 (9.08)
PSP, Mean (SD) 67.3 (10.41) 68.0 (10.01) 67.4 (10.33)
CGI-S, Median (Range) 3.0 (2;6) 3.0 (2;5) 3.0 (2;6)
  1. a includes native Hawaiian or other Pacific islander; b For PANSS and PSP: n = 178 (Treatment A), n = 26 (Treatment B), and n = 204 (Total); For CGI-S: n = 182 (Treatment A), n = 26 (Treatment B), and n = 208 (Total); PANSS- Positive and Negative Syndrome scale; PSP- Personal and Social Performance Scale; CGI-S- Clinical Global Impression Severity Score; PP- Paliperidone palmitate, BMI- Body Mass Index